Original Article

Effect of HIV Status and Charlson Comorbidity Index on COVID-19 Clinical Outcomes in a Case-Control Study

Authors: Rebecca C. Gerrity, MD, Melissa Parkinson, MD, Rachel Strength, MD, Chinelo N. Animalu, MD, Nathan Davidson, MD, Christian J. Fuchs, MD, Christopher D. Jackson, MD, Nathan A. Summers, MD, MSc

Abstract

Objectives: During the course of the coronavirus disease 2019 (COVID-19) pandemic, numerous comorbidities were identified as risk factors for increased morbidity and mortality. Few studies have examined human immunodeficiency virus (HIV) and COVID-19 co-infection and the impact of HIV on COVID-19 outcomes. In this study, we compared outcomes of people living with HIV with COVID-19 with a control group to examine outcomes.

Methods: We identified 45 people living with HIV admitted with COVID-19 to one of three large healthcare systems in Memphis, Tennessee, between March 1 and October 31, 2020. We matched the people living with HIV in a 1:1 fashion to a control group of COVID-19-positive patients without a recorded history of HIV and compared clinical outcomes. Nine pairs were not able to be optimally matched, so a sensitivity analysis was completed by repeating the same analyses in the primary analysis while excluding the nine mismatched pairs.

Results: Patients did not differ significantly in demographic variables due to the matching algorithm, and there was no significant difference in measured outcomes between people living with HIV and controls. A CD4 count of <200 cells per microliter was not significantly associated with increased morbidity or mortality. Controlling for HIV status, an elevated Charlson Comorbidity Index score of >3 was associated with increased intubation (P = 0.02), vasopressor use (odds ratio [OR] 4.81, P = 0.04), intensive care unit level of care (OR 4.37, P = 0.007), mortality (OR 7.14, P = 0.02), and length of overall hospital stay in days (P = 0.004).

Conclusions: We found no difference in outcomes of people living with HIV in comparison to matched controls based on HIV status but found that an increased Charlson Comorbidity Index score led to increased morbidity and mortality regardless of HIV status.
Posted in: Infectious Disease146 Acquired Immunodeficiency Syndrome (AIDS) And Human Immunodeficiency Virus (HIV) Infection21

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. World Health Organization. WHO COVID-19 dashboard. https://data.who.int/dashboards/covid19/cases. Accessed April 5, 2023.
 
2. Shelby County Health Department. COVID-19 data dashboard. https://www.shelbytnhealth.com/567/COVID-19-Data-Dashboard. Accessed April 5, 2023.
 
3. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2018–2022, in HIV Surveillance Supplemental Report. Atlanta, GA: Centers for Disease Control and Prevention; 2024;29.
 
4. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62:141–155.
 
5. Kenmoe S, Bigna JJ, Fatawou Modiyingi A, et al. Case fatality rate and viral aetiologies of acute respiratory tract infections in HIV positive and negative people in Africa: the VARIAFRICA-HIV systematic review and meta-analysis. J Clin Virol 2019;117:96–102.
 
6. Sheth AN, Patel P, Peters PJ. Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic. Curr HIV/AIDS Rep 2011;8:181–191.
 
7. Sheth AN, Althoff KN, Brooks JT. Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature. Clin Infect Dis 2011;52:219–227.
 
8. Osibogun A, Balogun M, Abayomi A, et al. Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. PLoS One 2021;16:e0248281.
 
9. Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2020;2:1069–1076.
 
10. Laracy J, Zucker J, Castor D, et al. HIV-1 infection does not change disease course or inflammatory pattern of SARS-CoV-2-infected patients presenting at a large urban medical center in New York City. Open Forum Infect Dis 2021;8:ofab029.
 
11. Hadi YB, Naqvi SFZ, Kupec JT, et al. Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study. AIDS 2020;34:F3–F8.
 
12. Danwang C, Noubiap JJ, Robert A, et al. Outcomes of patients with HIV and COVID-19 coinfection: a systematic review and meta-analysis. AIDS Res Ther 2022;19:3.
 
13. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–381.
 
14. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
 
15. Varol Y, Hakoglu B, Kadri Cirak A, et al. The impact of Charlson Comorbidity Index on mortality from SARS-CoV-2 virus infection and a novel COVID-19 mortality index: CoLACD. Int J Clin Pract 2021;75:e13858.
 
16. van Hal SJ, Jensen SO, Vaska VL, et al. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev 2012;25:362–386.
 
17. Ternavasio-de la Vega HG, Castano-Romero F, Ragozzino S, et al. The updated Charlson Comorbidity Index is a useful predictor of mortality in patients with Staphylococcus aureus bacteraemia. Epidemiol Infect 2018;146:2122–2130.
 
18. Ambrosioni J, Blanco JL, Reyes-Uruena JM, et al. Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV 2021;8:e294–e305.
 
19. Diez C, Del Romero-Raposo J, Mican R, et al. COVID-19 in hospitalized HIV-positive and HIV-negative patients: a matched study. HIV Med 2021;22:867–876.
 
20. Sigel K, Swartz T, Golden E, et al. Coronavirus 2019 and people living with human immunodeficiency virus: outcomes for hospitalized patients in New York City. Clin Infect Dis 2020;71:2933–2938.
 
21. Wang Y, Xie Y, Hu S, et al. Systematic review and meta-analyses of the interaction between HIV infection and COVID-19: two years' evidence summary. Front Immunol 2022;13: 864838.
 
22. Lopez-Aldeguer J, Iribarren JA, Valencia E, etal. Outcomes in HIV-infected patients admitted due to pandemic influenza. Enferm Infecc Microbiol Clin 2012;30:608–612.
 
23. Cohen C, Simonsen L, Sample J, et al. Influenza-related mortality among adults aged 25-54 years with AIDS in South Africa and the United States of America. Clin Infect Dis 2012; 55:996–1003.
 
24. Collins JP, Campbell AP, Openo K, et al. Outcomes of immunocompromised adults hospitalized with laboratory-confirmed influenza in the United States, 2011-2015. Clin Infect Dis 2020;70:2121–2130.